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Abstract
Background: the objective of this study was twofold:
1) Describe the use of antipsychotic treatments in ambulatory patients suffering from schizophrenia
in Belgium.
2) Evaluate to which extend antipsychotic treatment prescribing patterns are in accordance with
published treatment guidelines.
Method: A cross-sectional survey was carried out in 16 Belgian hospitals selected from a sample
of 67 hospitals. The hospitals were equally distributed between the north and south part of the
country and were representative of Belgian practice. During 2 months, participating psychiatrists
were asked to record the medication use as well as demographic parameters of all consecutive
ambulatory patients seen at their consultation or attending a day-hospital. Data concerning 1000
ambulatory patients with schizophrenia or schizoaffective disorder were collected.
Results: In Belgium, the use of atypical antipsychotics is frequent (69%) in ambulatory patients with
schizophrenia. In the overall sample, 73% receive only one antipsychotic drug. The majority of
patients are treated with drugs of only one antipsychotic drug group, either first- typical (29.8%)
or second-generation, atypical antipsychotics (53.2%). 15.8% of patients combine different types of
antipsychotics. Antipsychotic dosing is adequate for the majority of patients but about one fifth
receives a higher than recommended dose as per package inserts. Polypharmacy remains within
reasonable limits. The use of concomitant medication varies according the antipsychotic treatment:
patients who take second-generation antipsychotics only, receive the least additional drugs.
Conclusion:  Atypical antipsychotics appear to be the first line treatment for schizophrenic
psychosis. Psychiatrists working with ambulatory patients are well aware of treatment guidelines
and follow them quite adequately.
1. Background
Schizophrenia is a bio-psychosocial disorder where the
interaction between an innate vulnerability and biological
and psycho-social stressors determines whether an acute
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psychotic episode occurs or not [1-9]. The multidimen-
sional nature of the disorder implies that treatment
should focus on multiple aspects.
Although psychosocial and psychotherapeutic interven-
tions are essential in optimising outcome, the biological
treatment with antipsychotics is the cornerstone in the
treatment of schizophrenic psychosis. Compliance with
antipsychotic treatment is often a problem despite the
proven effectiveness of these drugs. The burdensome side
effects that regularly occur during treatment are an impor-
tant reason for non-compliance beside factors inherent to
the disease and fears of patients concerning the impact of
long-term antipsychotic use [1,2].
To minimise the occurrence of these side effects, several
guidelines have been formulated to optimise the use of
antipsychotic medication in schizophrenic patients.
Second generation antipsychotics (atypical or "novel"
antipsychotics, AAP) are regarded as the first line treat-
ment for schizophrenic patients because of their broader
symptomatological effectiveness in combination with a
more favourable side effect profile (especially a decreased
incidence of EPS) compared to first generation antipsy-
chotics ("classical", typical antipsychotics, CAP) [3-8].
For both CAP and AAP, the occurrence of side effects,
especially extra-pyramidal side effects, is related to the
dose administered: the risk of side effects increases paral-
lel to dose augmentations [9,10]. Adequate dosing is
therefore recommended, especially since there is no evi-
dence that higher doses will increase therapeutic effective-
ness.
Since both CAP and AAP can give rise to specific side
effects, combining them increases the risk of side effects
and is hence advised against [3]. When different antipsy-
chotics are combined medication schemes become more
complex. This increases the risk of non-compliance since
schizophrenic patients frequently suffer from severe cog-
nitive deficits [11]. For the same reason, the use of con-
comitant medication should be kept to a strict minimum.
A number of studies focusing on antipsychotic prescrip-
tion patterns have been conducted in several countries
[9,12-14]. In analogy with these studies, our study aims at
evaluating the use and dose of AAP in ambulatory patients
with schizophrenia in Belgium. Additionally, we want to
evaluate to which extend the medication use in ambula-
tory patients in Belgium is in accordance with the above
mentioned treatment recommendations. Also, we wanted
to compare the average daily dose used in ambulatory
patients as opposed to the patients attending a day-hospi-
tal patients and describe co-medication usage
2. Methods
A cross-sectional survey was carried out in 16 Belgian hos-
pitals, both university (n = 2) and non-university (n = 14)
selected from a sample of 67 hospitals. The hospitals were
equally distributed between the north and south part of
the country. During 2 months (July and august 2003),
participating psychiatrists were asked to record the medi-
cation use as well as demographic parameters of all con-
secutive ambulatory patients seen at their consultation or
day-hospital.
The following parameters were collected:
Age, sex, last hospitalisation, years since ambulatory sta-
tus, diagnosis, co-morbidities, GAF score, CGI, age at first
hospitalisation, level of education, living situation, occu-
pational status, psychiatric and somatic medication, labo-
ratory assessments, ECG, cognitive evaluation and
numbers of visits to the general practitioner.
The study was approved by the ethical committee of the
University Centre Sint-Jozef, Kortenberg, Belgium.
All patients with a DSM 295.xx diagnosis were included.
Each clinician included 21 patients on average
The following aspects of medication use were evaluated:
Firstly, it was evaluated if and to which extend CAP and
AAP are being prescribed in combination (Combination
therapy). Two forms of combination-therapy can be dis-
tinguished: on the one hand a combination of AAP and
Table 1: Antipsychotic treatment condition in ambulatory schizophrenic patients.
% patients
No AP or trial medication 1.2
Only CAP 29.8
Only AAP 53.2
Combination high potency CAP with AAP 9
Combination low potency CAP with AAP 6.8Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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high potency CAP, on the other hand a combination of
AAP and low potency CAP.
Secondly, we evaluated the prevalence of monotherapy.
Two meanings of the concept "monotherapy" can be dis-
tinguished: monotherapy can refer to the use of drugs of
only one antipsychotic class, either AAP or CAP, irrespec-
tive of the number of different drugs administered. In the
remaining part of the text, we will refer to this form of
monotherapy with the labels "Only AAP" and "Only
CAP".
A second meaning of monotherapy refers to the use of
only one antipsychotic agent, we will refer to this defini-
tion as "real monotherapy". For the total study sample
and for each of the treatment conditions defined above,
the occurrence of actual monotherapy and the number of
different antipsychotics that are prescribed simultane-
ously, as well as the concomitant medication adminis-
tered, was evaluated. The average daily dose administered
for CAP and AAP separately was also assessed.
Descriptive statistics were applied for basic demographic
and clinical data as well as for data on medication usage.
Comparisons between antipsychotic treatment groups or
between patients groups for continuous variables are cal-
culated by means of an ANOVA. For categorical data a chi-
square test was used.
3. Results
3.0 Participating sites
The overall geographical distribution of the sites does not
differ from the National distribution from the National
Institute of Health. Data from 1000 patients were col-
lected by the 16 sites
3.1. Patient characteristics
From the 1000 patients with a DSM-IV 295.xx diagnosis,
737 are treated ambulatory and 263 are attending a day
hospital but live in the community.
Paranoid schizophrenia is the most frequently observed
diagnosis (58.2%), followed by schizoaffective disorder
(16.3%) and undifferentiated schizophrenia (12.5%).
The other subtypes were present in less than 10% of
patients. 7% of patients have an additional diagnosis on
axis I, 16% on axis II. The majority of these patients are
male (64.1%) and unemployed (79.5%). The mean age in
the population is 40.5 years (std11.6). Patients have been
ill for 14.7 years (std 10.4) on average and have on aver-
age been admitted 5 times (std 4.3).
Patients' mean GAF-score was 62 (std 12.3) [15]. 36.4% of
patients have a CGI of moderately ill, another 21.8% have
more severely ill CGI-scores [16]. The correlation between
GAF and CGI is -0.87 (p < .0001).
At the time of assessment, half of the patients (50.9%)
had been treated ambulatory for more than two years.
Combination of different AP Figure 1
Combination of different AP.
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Table 2: Number of different AP.
% Patients Number of AP (AAP + CAP)
1234
Only AAP 93.8 6.2 0 0
Combination low potency 
CAP with AAP
0 86.8 13.2 0
Combination high potency 
CAP with AAP
0 78.9 16.7 4.4
Only CAP 74.5 20.8 4.4 0.3
Total population 73 22.8 3.7 0.5Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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3.2. Medication use and distribution
3.2.1. Use of antipsychotics
On average, patients receive 1.3 different antipsychotic
drugs (std 0.6). The prevalence of the predefined treat-
ment conditions is shown in table 1.
From the above table, we can see there is a high usage of
AAP in this population: 69% of patients are treated with
AAP. One fourth (24.7%) of CAP are used for sedation (as
indicated by the clinician, and in the analysis also based
on type of CAP and dose).
37.9% of CAP are administered through depot injections.
About one quarter (24.2%) of the patients treated with
depot injections use additional AAP. In the total popula-
tion, 21.5% of the patients are treated with depot injec-
tions.
As can be seen in table 2, real monotherapy, i.e. the use of
one and only one antipsychotic, is observed in almost
three quarters of patients (73%). Only 4.2% of patients
combine more than two different antipsychotics.
The proportion, in which the different AAP are used in
monotherapy, is comparable for most AAP and is about
70%. As opposed to the other drugs, quetiapine is used in
monotherapy in about 50% of the patients (Figure 1).
Risperidone is the most frequently used AAP used by
34.4% of patients treated with AAP. Olanzapine is used by
27.4%, clozapine by 18.9%, quetiapine by 9.2%, amisul-
pride by 8.9%, sertindole by 0.7 and aripiprazole by 0.6%
of patients prescribed AAP (both aripiprazole and sertin-
dole were not commercially available at the time of the
study).
3.2.2. Antipsychotic doses
3.2.2.1. Dose of Typical Antipsychotic (AP)
Table 3 gives the average daily CAP-dose per patient
expressed in haloperidol equivalents. To evaluate the
occurrence of overdosing, we calculated the percentage of
patients being treated with doses below, within or above
the advocated dose range of 5 to 10 mg haloperidol
equivalents8. 49.5% of patients receive a low dose of CAP
(mean 2.3 mg, std 1.3) and 19.5% of patients get a higher
than recommended dose of CAP (mean 18.8 mg, std 9.6).
3.2.2.2. Dose of Atypical Antipsychotic use
For the most frequently used AAP and for the total group
of AAP, average daily doses for each of the defined dose
ranges are given in table 4. The occurrence of under- and
overdosing, relative to the label instructions, is displayed
in figure 2.
3.2.3. Concomitant medication use
The patients of this sample use 2.97 (std 1.8) different
drugs on average of which 1.7 (std 1.6) are psychotropic
agents and somatic medication.
One third of the patients (33%) are treated with more
than three different drugs. Psychotropic medications
other than antipsychotics are used by 68.7% of patients
and 28% receive somatic medication. The frequency with
which different categories of psychotropic medication are
used is shown in table 5.
The total number of additional psychotropic medication
patients use is significantly influenced (p < .001) by antip-
sychotic treatment. The use of benzodiazepines (p < .01),
anticholinergics (p < .01) and antidepressants (p < .01)
are all influenced by the type of antipsychotic treatment as
can be seen in Figure 3.
Table 4: Mean daily dose per patient for the most frequently used AAP.
Mean dose STD N
Olanzapine 14.9 6.9 200
Risperidone 3.7 1.8 251
Clozapine 286.4 146.5 138
Quetiapine 600 249.2 67
Amisulpride 596.2 269 65
Table 3: Mean equivalent dose per patient for CAP.
Mean equivalent Dose STD N
High potency CAP 6.8 6.3 371
Low potency CAP 1.1 0.6 131
All CAP 6.0 6.2 456Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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Sedative CAP are combined with benzodiazepines in 8%
of patients.
The use of anticholinergics as a function of antipsychotic
treatment is specified in table 6 and figure 4.
From figure 4 and table 6 it appears that the advantage of
AAP regarding EPS vanishes when AAP are combined with
CAP. Even when AAP are combined with sedative CAP,
anticholinergic use increases. The negative influences of
adding CAP to AAP is also observed when the most fre-
quently used AAP are considered separately (Figure 4).
Patients with schizophrenia additionally receive 0.3 (std
0.5) somatic drugs on average. Almost three in four
patients (72%) do not take any somatic drugs. Women
take significantly more somatic drugs than men (p <
.0005). Only 7.8% of female patients use contraceptive
medication. Somatic drug use increases with age (p <
.0005). 3% of patients are treated for diabetes, 1.3% for
lipid abnormalities.
3.3. Clinical care
Every 5.4 weeks on average, ambulatory patients are in
contact with their psychiatrist. Patients in day care are in
contact with the treatment team 3.4 days a week on aver-
age. Ambulatory patients less frequently (Mean 0.7 visits)
contact a medical specialist than patients in day care
(Mean 1.2 visits) (p < .05).
Almost half of the patients (48.6%) do not have a GP. This
problem is more pronounced in day care patients (61.6%)
as compared to ambulatory patients (44%). Annually,
ambulatory patients see their GP more frequently (Mean
3.3 visits) than patients in day care (Mean 1.9 visits) (p <
.005). Patients on depot medication more frequently see
their GP than patients not treated with depot medication
(p < .0005).
Female patients more frequently visit their GP than male
patients (p < .0005). The number of visits to a GP signifi-
cantly (p < .0005) increases with age.
About one fourth of patients have an ECG performed in
the past 6 months. Cognitive functioning is evaluated in
7.5% of patients and only 39.6% undergo a laboratory
assessment in the last 6 months (including compulsory
haematological assessment in patients treated with cloza-
pine). Regular screening for metabolic side-effects is only
performed in 3 sites.
3.4. Differences between ambulatory patients and patients 
in day care
3.4.1. Demographic and clinical characteristics
With respect to diagnosis, gender and educational level,
there are no significant differences between patients
Use of concomitant medication as a function of antipsychotic  treatment Figure 3
Use of concomitant medication as a function of antipsychotic 
treatment.
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Frequency (%) of high, low and normal doses for the most 
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Table 5: Use of concomitant psychotropic medication.
Psychotropic medication % patients using a drug from a medication group
Anticholinergics 21.6
Benzodiazepines 36.2
Mood stabilisers 15.2
Antidepressants 39.1Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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treated ambulatory and patients in day care. Compared to
ambulatory patients, patients in day care more frequently
are unemployed (p < .01).
Patients in day hospital (mean age 39.3 years, std 12.4)
are significantly younger than ambulatory patients (mean
age 41 years, std = 11.5). Ambulatory patients have a sig-
nificantly (p < .0005) higher GAF-score (Mean 64.3) than
patients in day hospital (Mean 55.8).
The CGI-scores are distributed significantly different (p <
.0001) for ambulatory patients and patients in day hospi-
talisation, ambulatory patients are less severely ill.
The duration of ambulatory care since last hospitalisation
is significantly longer than the duration of treatment in
day care since last hospitalisation which might suggest a
more stable condition in ambulatory patients.
3.4.2. Antipsychotic medication
The distribution of patients over the different antipsy-
chotic treatments defined is significantly different for
ambulatory patients and patients in day care (p < .01).
Compared to ambulatory patients, patients in day hospi-
talisation less frequently use olanzapine and clozapine in
monotherapy (p < .05). For some of the AAP as well as for
the group of AAP as a whole, dosing is significantly higher
in the day care group (Table 7). For clozapine and the
group of AAP in general the frequency of over- and under-
dosing also differs as a function of patient group (p < .05)
(Figure 5).
3.4.3. Concomitant medication
Outpatients (Mean 2.8, std 1.7) take significantly less dif-
ferent drugs than patients in day care (Mean 3.4, std 2).
Patients in day care more frequently (27%) use anti-
cholinergics than ambulatory patients (19.7%) (p < .05).
Somatic medication is also used significantly less fre-
quently by ambulatory patients. Female patients in day
care more frequently use oral contraception.
4. Discussion
In the total sample, representing ambulatory and day-care
patients, almost three in four patients (73%) are treated
with one antipsychotic: this percentage is higher in the
groups of patients only treated with AAP (93.8%) as com-
pared to patients only receiving CAP (74.5%). Obviously,
patients on combination therapy receive at least two dif-
ferent antipsychotics.
Frequency (%) of now, high, and normal dosing for clozapine  and all AAP Figure 5
Frequency (%) of now, high, and normal dosing for clozapine 
and all AAP.
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Table 6: Use of anticholinergics as a function of antipsychotic treatment.
Antipsychotic treatment % of patients using anticholinergics
Only AAP 7.9a
Combination sedative CAP with AAP 26.5b
Combination incisive CAP with AAP 42.2b
Only CAP 39.6b
a, b: treatment conditions with a different subscript differ at .05-level
Use of anticholinergics (%) as a function of antipsychotic  treatment Figure 4
Use of anticholinergics (%) as a function of antipsychotic 
treatment.
7,9
35,4
17,2
51,1
5,5
32,1
1,4
28,1
0
33,3
7
25
39,6
0
10
20
30
40
50
60
Only AAP
AAP + CAP
Ris
Ris + CAP
Clo
Clo + CAP
Ola
Ola + CAP
Ami
Ami + CAP
Quet
Quet + CAP
Only CAP
%
 
o
f
 
p
a
t
i
e
n
t
s
 
u
s
i
n
g
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
sClinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
Page 7 of 11
(page number not for citation purposes)
In ambulatory patients in Belgium, AAP are frequently
used: 69% of patients are treated with AAP either in mon-
otherapy, or in combination with CAP. Second generation
antipsychotics represent the majority prescribed antipsy-
chotics. The percentage of patients treated with CAP is
clearly lower: 45.6%.The most common antipsychotic
treatment is monotherapy of AAP: 53.2%. Monotherapy
of CAP occurs in 29.8% of patients. Only 15.8% receive a
combination of AAP and CAP. These results are in-line
with a recent comparable study carried out in France
which included 1861 ambulatory patients [17].
For both AAP and CAP, average daily doses lie within the
advocated dose range. The majority of the patients receive
drug doses that fall under or within the advocated dose
range. Dosing is similar in both patients groups, when dif-
ferences are observed, day care patients receive the highest
doses. Higher than recommended doses are being used in
about 20% of patients, both for CAP and AAP.
Beside antipsychotic medication, patients on average
receive 1.7 additional drugs. Day care patients receive
more concomitant medication than outpatients. Espe-
cially the use of anticholinergics and somatic drugs
appears increased in the former group. The low prevalence
of adequate contraception in female patients is problem-
atic.
In the total population, the use of additional medication
appears to be influenced by antipsychotic treatment.
Patients only treated with AAP generally need less con-
comitant medication than patients in other treatment
conditions. Anticholinergics in particular are used signifi-
cantly less by patients only treated with AAP. If AAP are
combined with CAP, even only for sedation, the use of
anticholinergics increases significantly. This clearly indi-
cates that the EPS advantage of AAP disappears when AAP
are combined with CAP. This confirms that AAP are the
first line treatment choice for schizophrenic psychosis.
The percentage of patients treated for diabetes and lipid
abnormalities is fairly low suggesting under-diagnosing
corroborated by the fact that systematic screening for met-
abolic disorders is restricted to a limited number of sites.
This is in agreement with recent surveys still indicating
low awareness of clinicians about metabolic side-effects of
antipsychotic medication, while there is a large body of
evidence suggesting that people with schizophrenia are a
high-risk group for the development of metabolic abnor-
malities [18-24].
Overall the somatic follow-up of patients with schizo-
phrenia could be improved by active involvement of GP's.
About 50% of patients studied do not have a GP.
Cognitive evaluation and ECG-monitoring are not done
on a routine basis in clinical care.
In general, there are no important differences between
outpatients and patients in day care. As can be expected,
day care patients are more severely ill than outpatients.
Other differences between both patient groups, like the
increased use of concomitant medication and higher dose
of antipsychotic medication by day hospitalisation
patients, can be interpreted as a consequence of this differ-
ence in illness severity.
Although progress has been made in the therapeutic care
of patients with schizophrenia and treatment is being pro-
vided on an ambulatory basis for the majority of patients
in Belgium, most of them remain unemployed and
dependent on social disability incomes which constitutes
Table 7: Dosages AAP per patient group.
Mean Dose STD N p
Olanzapine Ambulatory 14.3 6.5 146 p < .05
Day Care 16.8 7.4 54
Total 14.9 6.9 200
Risperidone Ambulatory 3.7 1.9 188 ns
Day Care 3.8 1.5 63
Total 3.7 1.8 251
Clozapine Ambulatory 269.4 154 98 p < .05
Day Care 328.1 117.6 40
Total 286.4 146.5 138
Quetiapine Ambulatory 582.1 267.4 39 ns
Day Care 625 223.8 28
Total 600 249.2 67
Amisulpride Ambulatory 572.8 266.6 46 ns
Day Care 652.6 273.6 19
Total 596.2 269 65Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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a high societal burden [25]. Efforts should be made to
both support adequate treatment choices as well as overall
care including social integration
5. Conclusion
Our results show that Belgian psychiatrists treating ambu-
latory patients are well aware of guideline recommenda-
tions on the use of antipsychotic medication, and
generally follow them quite adequately. The use of AAP
with their broader symptomatological efficacy and more
favourable side effect profile appears well established in
clinical practice: 69% of patients are treated with AAP. The
large majority of patients (73%) are treated with only one
antipsychotic. Actual monotherapy is even more frequent
(93.8%) when patients are only treated with AAP.
The latter group also receives less concomitant medication
than patients in other treatment conditions. Especially
anticholinergic use is less frequent in patients only treated
with AAP. This finding indirectly suggests less EPS in
patients only treated with AAP.
Medication schemes are hence simplest in this patient
group which is expected to positively influence compli-
ance. Dosing for both CAP and AAP generally falls within
the advocated dose ranges.
At the time of the study there was limited awareness in cli-
nicians about metabolic side-effects of antipsychotic med-
ication.
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Table 5: Use of concomitant psychotropic medication.
Psychotropic medication % patients using a drug from a medication group
Anticholinergics 21.6
Benzodiazepines 36.2Clinical Practice and Epidemiology in Mental Health 2006, 2:11 http://www.cpementalhealth.com/content/2/1/11
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Mood stabilisers 15.2
Antidepressants 39.1
Table 5: Use of concomitant psychotropic medication. (Continued)
Use of concomitant medication as a function of antipsychotic  treatment Figure 3
Use of concomitant medication as a function of antipsychotic 
treatment.
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Table 6: Use of anticholinergics as a function of antipsychotic treatment.
Antipsychotic treatment % of patients using anticholinergics
Only AAP 7.9a
Combination sedative CAP with AAP 26.5b
Combination incisive CAP with AAP 42.2b
Only CAP 39.6b
a, b: treatment conditions with a different subscript differ at .05-level
Use of anticholinergics (%) as a function of antipsychotic  treatment Figure 4
Use of anticholinergics (%) as a function of antipsychotic 
treatment.
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Table 7: Dosages AAP per patient group.
Mean Dose STD N p
Olanzapine Ambulatory 14.3 6.5 146 p < .05
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Total 14.9 6.9 200
Risperidone Ambulatory 3.7 1.9 188 ns
Day Care 3.8 1.5 63
Total 3.7 1.8 251
Clozapine Ambulatory 269.4 154 98 p < .05
Day Care 328.1 117.6 40
Total 286.4 146.5 138
Quetiapine Ambulatory 582.1 267.4 39 ns
Day Care 625 223.8 28
Total 600 249.2 67
Amisulpride Ambulatory 572.8 266.6 46 ns
Day Care 652.6 273.6 19
Total 596.2 269 65
Table 7: Dosages AAP per patient group. (Continued)
Frequency (%) of now, high, and normal dosing for clozapine  and all AAP Figure 5
Frequency (%) of now, high, and normal dosing for clozapine 
and all AAP.
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